[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of East Anglia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100590768","coronary-bifurcations-with-ischaemia-and-flow-assessment-100590768",false,"NCT06971718","Coronary Bifurcations With Ischaemia and Flow Assessment","Drug Coated Balloons in Coronary Bifurcation Lesions. A Feasibility Study Looking at Computational Flow Dynamics, Ischaemic and Anatomical Changes to the Bifurcation","Inclusion Criteria:\n\n* Age 18 or over\n* Any bifurcation lesion amenable to a provisional main vessel treatment strategy\n* A main vessel diameter of 2.5mm or more and side branch diameter of \\>2mm\n* Any patient with stable angina, silent ischaemia, unstable angina or NSTEMI\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Cardiogenic shock\n* LVEF \\\u003C30%\n* STEMI (as unable to give informed consent)\n* eGFR \\\u003C30\n* Severe asthma contraindicating use of adenosine\n* High degree AV block on 12 lead ECG precluding the use of adenosine\n* Pregnancy\n* Inability to consent\n* Left main stem coronary bifurcation lesions","ALL","18 Years",{"count":19,"type":20},24,"ESTIMATED","OBSERVATIONAL","The coronary arteries are blood vessels that provide oxygen rich blood to the muscle of the heart. If these vessels become narrowed or blocked, this can lead to chest pain (called angina) or heart attacks. Narrowings are usually treated using metal scaffolds called drug eluting stents. However, in one in five cases where the narrowing occurs at a branching point, treating it with stents is more challenging and can cause complications. A possible alternative treatment is using a special type of balloon called a drug-coated balloon. This balloon is inflated in the blood vessel and releases medicine to help widen the blood vessel and the procedure is completed without leaving any metallic scaffold behind.\n\nThis study aims to compare drug coated balloons with drug eluting stents to see which treatment works better for narrowing that occurs at branching points. We will used advanced imaging techniques to create computer models of blood flow in the vessels, and we will follow up with patients over tie to see how well the treatments work.",[24],"Coronary Bifurcation Lesions",[26,27,28],"Drug coated balloons","Coronary bifurcation lesions","Computational flow dynamics","RECRUITING","2025-05-06",{"date":32,"type":33},"2025-05-14","ACTUAL",{"date":35,"type":33},"2023-10-10",{"date":37,"type":20},"2026-06-01",{"name":39,"class":40},"University of East Anglia","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100571069","phase-2-empa-esus-a-randomised-control-trial-to-investigate-the-impact-of-empagliflozin-on-left-atrial-function-in-patients-with-embolic-stroke-of-undetermined-source-100571069","NCT06715449","EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source","EMPA-ESUS","Inclusion Criteria:\n\n* Age over 18 years\n* Patient has had an embolic stroke of undetermined source, defined as:\n\n  * Ischaemic stroke or transient ischaemic attack diagnosed clinically + supporting radiological features on CT or MRI imaging\n  * No clinically significant extracranial or intracranial atherosclerosis found on neck imaging\n  * No evidence of prevalent cardioembolic source of embolism - atrial dysrhythmia, cardiac thrombus, prosthetic valve, cardiac tumours, mitral stenosis, recent MI, LVEF\\\u003C35%, valvular vegetations, or infective endocarditis\n\nAND\n\n* No other specific stroke aetiology identified (pro-thrombotic states, arteritis, dissection, drug abuse)\n* Patient has been referred for an implantable loop recorder implant to investigate possible atrial dysrhythmia\n* Ability to give written, informed consent\n\nExclusion Criteria:\n\n* Prevalent atrial fibrillation or atrial flutter\n* Subsequent demonstration of a cardio-emoblic source\n* Pre-existent indication for SGLT2i including heart failure with a reduced ejection fraction and Type 1 or Type 2 diabetes mellitus\n* Contraindication to the commencement of SGLT2i including a history of, or risk factors for diabetic ketoacidosis, such as restricted food intake or a history of alcohol abuse\n* Hypersensitivity to the active substance or to any of the excipients of empagliflozin\n* Presence of alternate implantable cardiac devices such as a pacemaker or defibrillator, that would make ILR utilisation redundant\n* Any condition that may confound the results or interfere with participation such as dementia\n* An unwillingness to participate",{"count":50,"type":20},100,"INTERVENTIONAL",[53,54],"PHASE2","PHASE3","Atrial fibrillation (AF) is the most common heart rhythm problem in the adult population. There is a five-fold increase in stroke risk in patients with AF. Whilst there has been considerable advances in AF management including improvement in ablation therapy, preventing AF remains an unmet need.\n\nOne promising avenue is a group of medications called Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, which has been studied in people with diabetes, kidney disease and weak heart muscle. These medicines were consistently found to lower the risk of developing AF. This can be promising for patients who have suffered a stroke for unclear reasons, where a significant proportion are subsequently found to have short periods of AF. Often prior to AF development, patients may have changes in the structure or function of the top chambers of their heart (the atria). This may provide a useful marker for us to understand whether SGLT2i impacts AF risk.\n\nAim of research study:\n\nThe aim of this study is to investigate whether the use of the drug empagliflozin, an SGLT2 inhibitor, prevents changes in the left atrium associated with future AF development. Using advanced imaging techniques and continuous rhyth monitoring we intend to study the effect of SGLT2 inhibitors on left atrial function and arrhythmia occurence.\n\nStudy design:\n\nPatients who are undergoing an implantable loop recorder insertion, to detect AF following a stroke, will be invited for participation. Eligible consenting patients will have a baseline assessment with echocardiography, electrocardiogram and anthropometric measures. They will then be randomised to receive either the SGLT2i alongside usual stroke care for 6 months, or usual stroke care alone. All patients will be monitored remotely via their loop recorder, and will undergo repeat electrocardiogpahic, echocardiographic and anthropometric assessment at 6 months. This way, we aim to investigate whether the SGLT2 inhibitor causes changes in atrial parameters that may be associated with future AF development.",[57,58],"Embolic Stroke of Undetermined Source","Atrial Fibrillation New Onset",[60],"Atrial strain","2024-11-28",{"date":63,"type":33},"2024-12-04",{"date":65,"type":33},"2024-11-22",{"date":67,"type":20},"2029-03",{"name":39,"class":40},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100448079","heart-failure-with-preserved-ejection-fraction-evaluation-and-recognition-by-cmr-100448079","NCT05114785","Heart Failure With Preserved Ejection Fraction: Evaluation and Recognition by CMR","PReserved Ejection Fraction Evaluation and Recognition by Cardiac Magnetic Resonance","PREFER-CMR","Inclusion Criteria:\n\n1. Adults: age≥18 years.\n2. Typical HF symptoms (NYHA stage\\>I) within the last six months.\n3. Raised NTproBNP (\\>400 pg\u002Fml)\n4. EF\\>50 % with the absence of structural heart disease on TTE (except left ventricular hypertrophy or left atrial enlargement).\n\nExclusion Criteria:\n\n1. Patients unable\u002Funwilling to provide informed consent.\n2. Bodyweight\\>120 kg or inability to lie flat\u002Fstill.\n3. Contraindication for invasive workup (allergy to contrast, severe renal insufficiency with estimated glomerular filtration rate (eGRF)\\\u003C30 ml\u002Fmin).\n4. Contraindications for a contrast-enhanced CMR study (allergy to contrast, incompatible devices or implants, severe claustrophobia).\n5. Previous medical history of EF \\\u003C50%\n6. Pregnancy\n\nThe extended observational arm of the study will have wider eligibility criteria\n\n\\- Patients undergoing cardiac MRI for clinical indications irrespective of EF",{"count":50,"type":20},"Heart failure with preserved ejection fraction (HFpEF) is a common and growing condition with a poor prognosis but the pathophysiology and management are still being investigated. The PREFER-CMR project aims to evaluate and validate the application of novel 4D cardiac magnetic resonance flow dynamic methods to measure left ventricular pressures and validate these measurements with direct pressure measurement by coronary angiography. This is a prospective observational study of patients with HFpEF undergoing clinical evaluation with coronary angiography who will also undergo contemporaneous cardiac MRI. The primary outcome will be the level of agreement between the two methods using angiography as the reference method.",[80,81],"Heart Failure With Preserved Ejection Fraction","Heart Diseases",[83,84,85],"Heart failure","hemodynamics","magnetic resonance imaging","NOT_YET_RECRUITING","2021-12-13",{"date":89,"type":33},"2022-01-05",{"date":91,"type":20},"2022-01",{"date":93,"type":20},"2032-01",{"name":39,"class":40},""]